Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 70.30
+0.65 (0.93%)
Oct 6, 2026, 5:38 PM CET
Pharma Mar Revenue
In the year 2025, Pharma Mar had annual revenue of 221.39M EUR with 26.61% growth. Pharma Mar had revenue of 46.25M in the quarter ending June 30, 2026, a decrease of -4.36%.
Revenue
221.39M
Revenue Growth
+126.67%
P/S Ratio
5.52
Revenue / Employee
432.96K
Employees
505
Market Cap
1.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 221.39M | 46.54M | 26.61% |
| Dec 31, 2024 | 174.86M | 16.70M | 10.56% |
| Dec 31, 2023 | 158.15M | -38.19M | -19.45% |
| Dec 31, 2022 | 196.34M | -33.49M | -14.57% |
| Dec 31, 2021 | 229.83M | -40.13M | -14.87% |
| Dec 31, 2020 | 269.96M | 184.14M | 214.57% |
| Dec 31, 2019 | 85.82M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.42B |
| Almirall | 1.16B |
| Laboratorios Farmaceuticos Rovi | 773.05M |
| Faes Farma | 711.06M |
| Laboratorio Reig Jofre | 337.73M |
| Clínica Baviera | 320.67M |
| Prim, S.A. | 250.65M |
| Atrys Health | 147.68M |
Pharma Mar News
- 2 months ago - Pharma Mar Slides: Corporate presentation - Filings
- 2 months ago - Pharma Mar Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Pharma Mar Earnings release: Q2 2026 - Filings
- 2 months ago - Pharma Mar Quarterly report: Q2 2026 - Filings
- 3 months ago - Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan - TheFly
- 5 months ago - Pharma Mar Earnings release: Q1 2026 - Filings
- 5 months ago - Pharma Mar Quarterly report: Q1 2026 - Filings
- 5 months ago - Pharma Mar initiated with a Buy at BTIG - TheFly